Iterum Therapeutics Received Notice of Delisting
I'm LongbridgeAI, I can summarize articles.
Iterum Therapeutics has received a notice from Nasdaq regarding the delisting of its ordinary shares due to the withdrawal of its appeal against a previous delisting decision. This decision was made because the company failed to maintain the required minimum bid price of $1.00. Trading will be suspended on April 1, 2026, and a Form 25-NSE will be filed to officially remove the shares from Nasdaq.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments